What is the Difference Between Cell Free DNA and Circulating Tumor DNA?

Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are both found in the bloodstream, but they have different origins and characteristics.

Cell-free DNA (cfDNA):

cfDNA consists of small fragments of DNA released into the bloodstream by both normal and cancerous cells.
A great proportion of cfDNA comes from normal cells of the body, and a small part of it is related to tumors.
cfDNA can be derived from normal cells, including normal leukocytes that undergo apoptosis, and cancer cells.
It is detectable in healthy volunteers, patients without cancer, patients with benign tumors, and cancer patients.

Circulating tumor DNA (ctDNA):

ctDNA is the portion of circulating DNA specifically derived from cancer cells.
It is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors.
As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down, and their contents, including DNA, are released into the bloodstream.
ctDNA is typically shorter in length compared to cfDNA.

In summary, cfDNA is a broader term that includes both normal and tumor-related DNA fragments, while ctDNA specifically refers to the portion of circulating DNA derived from cancer cells. Both cfDNA and ctDNA have potential applications in cancer diagnosis, treatment, and monitoring, but they differ in their origins and characteristics.

On this page

What is the Difference Between Cell Free DNA and Circulating Tumor DNA?

Comparative Table: Cell Free DNA vs Circulating Tumor DNA

Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are two types of genetic material that can be found in the bloodstream. They have gained attention for their potential role in cancer management, particularly in the area of liquid biopsies. Here is a table highlighting the differences between cfDNA and ctDNA:

Feature	Cell-free DNA (cfDNA)	Circulating Tumor DNA (ctDNA)
Origin	cfDNA comes from various sources, including normal and tumor cells. ctDNA is a small portion of cfDNA that originates from tumor cells, including primary tumors, metastatic sites, or circulating tumor cells (CTCs).
Proportion	A great proportion of cfDNA comes from normal cells, with a small part related to tumors.	ctDNA is a minor fraction of cfDNA, specifically associated with tumors.
Detection	cfDNA can be detected in the blood of healthy individuals and has been studied since the 1940s. The first somatic point mutations in cfDNA were identified in 1994, leading to more research on its potential role in cancer management.	ctDNA detection is more recent, with technological advancements and methodological improvements enabling its identification and analysis.
Applications	Both cfDNA and ctDNA have potential applications in cancer management, such as diagnosis, treatment selection, and monitoring disease progression. However, some studies focus specifically on the role of ctDNA in cancer management.
Challenges	One of the challenges in cfDNA and ctDNA research is understanding how these biomarkers should be interpreted across various clinical contexts and overcoming technological limitations in their detection and analysis.

Despite the potential of cfDNA and ctDNA in cancer management, more research is needed to fully understand their implications and incorporate them into routine clinical practice.

Guilherme Mazui

Guilherme Mazui is graduated in journalism from the Federal University of Minas Gerais (UFMG) and a master's degree in Communication from the University of São Paulo (USP). In addition, he has experience in advertising writing and has worked as a content editor in several companies.